Access the world's leading financial data and tools

Subscribe for $2
Overview
Profile

Revolution Medicines stock

RVMD
US76155X1000
A2PYWG

Price

41.34
Today +/-
+0.10
Today %
+0.27 %

Revolution Medicines stock price

%
Weekly
Details

Price

ⓘ

Overview

The Quote Chart provides detailed and dynamic insights into the Revolution Medicines stock's performance, showcasing daily, weekly, or monthly aggregated quotes. Users can switch between different time frames to analyze the stock's progression meticulously and make informed investment decisions.

Intraday Feature

The intraday feature provides real-time data, allowing investors to view the Revolution Medicines stock’s price fluctuations within the trading day, facilitating timely and strategic investment decisions.

Total Return and Relative Price Change

View the total return of the Revolution Medicines stock to gauge its profitability over time. The relative price change, based on the first quote available in the selected timeframe, offers insights into the stock’s performance, assisting in evaluating its investment potential.

Interpretation and Investment

Utilize the comprehensive data presented in the Quote Chart to analyze Revolution Medicines's market trends, price movements, and potential returns. Make informed investment choices by comparing different time frames and evaluating intraday data for optimized portfolio management.

Revolution Medicines Stock Price History

DateRevolution Medicines Price
2/24/202541.34 undefined
2/23/202541.23 undefined
2/20/202541.34 undefined
2/19/202542.26 undefined
2/18/202542.34 undefined
2/17/202541.47 undefined
2/13/202540.67 undefined
2/12/202541.32 undefined
2/11/202542.00 undefined
2/10/202541.45 undefined
2/9/202542.06 undefined
2/6/202542.19 undefined
2/5/202543.57 undefined
2/4/202544.25 undefined
2/3/202542.32 undefined
2/2/202542.14 undefined
1/30/202542.95 undefined
1/29/202543.07 undefined
1/28/202540.92 undefined
1/27/202540.92 undefined

Revolution Medicines Revenue, EBIT, Net Income

  • 3 years

  • 5 years

  • 10 years

  • 25 Years

  • Max

Revenue
EBIT
Net Income
Details

Revenue, EBIT and Profit

ⓘ

Understanding Revenue, EBIT, and Income

Gain insights into Revolution Medicines, a comprehensive overview of its financial performance can be obtained by analyzing the Revenue, EBIT, and Income chart. Revenue represents the total income generated by Revolution Medicines from its primary operations, showcasing the company’s ability to attract and retain clients. EBIT, or Earnings Before Interest and Taxes, indicates the company’s operational profitability, free from the influence of tax and interest expenses. The Income section reflects Revolution Medicines’s net earnings, an ultimate measure of its financial health and profitability.

Yearly Analysis and Comparisons

Observe the yearly bars to understand the annual performance and growth of Revolution Medicines. Compare the Revenue, EBIT, and Income to evaluate the company’s efficiency and profitability. A higher EBIT compared to the previous year suggests an improvement in operational efficiency. Likewise, an increase in Income indicates enhanced overall profitability. Analyzing the year-to-year comparison assists investors in understanding the company’s growth trajectory and operational efficiency.

Utilizing Expectations for Investment

The expected values for the forthcoming years offer investors a glimpse into Revolution Medicines’s anticipated financial performance. Analyzing these projections alongside historical data aids in making informed investment decisions. Investors can gauge the potential risks and returns, aligning their investment strategies accordingly to optimize profitability and mitigate risks.

Investment Insights

Leveraging the comparison between Revenue and EBIT helps in assessing Revolution Medicines’s operational efficiency, while the Revenue and Income comparison reveals the net profitability after accounting for all expenses. Investors can derive valuable insights by meticulously analyzing these financial parameters, laying the foundation for strategic investment decisions aimed at capitalizing on Revolution Medicines’s growth potential.

Revolution Medicines Revenue, EBIT and net profit per share

DateRevolution Medicines RevenueRevolution Medicines EBITRevolution Medicines Net Income
2030e2.8 B undefined0 undefined1.51 B undefined
2029e1.51 B undefined311.49 M undefined323.99 M undefined
2028e674.84 M undefined-255.87 M undefined-148.84 M undefined
2027e205.56 M undefined-645.27 M undefined-558.7 M undefined
2026e4.68 M undefined-827.34 M undefined-794.88 M undefined
2025e5.98 M undefined-768.73 M undefined-744.88 M undefined
2024e306,000 undefined-680.64 M undefined-653.26 M undefined
202311.58 M undefined-487.19 M undefined-436.37 M undefined
202235.38 M undefined-258.28 M undefined-248.71 M undefined
202129.39 M undefined-188.01 M undefined-187.09 M undefined
202042.98 M undefined-110.7 M undefined-110.38 M undefined
201950.04 M undefined-54.12 M undefined-61.9 M undefined
201820.17 M undefined-40.33 M undefined-48.82 M undefined
20170 undefined-31.13 M undefined-34.89 M undefined

Revolution Medicines Income Statement, Balance Sheet, Cash Flow Statement

  • Simple

  • Expanded

  • Income Statement

  • Balance Sheet

  • Cashflow

 
REVENUE (B)REVENUE GROWTH (%)GROSS MARGIN (%)GROSS INCOME (M)NET INCOME (B)NET INCOME GROWTH (%)SHARES (M)DOCUMENTS
20172018201920202021202220232024e2025e2026e2027e2028e2029e2030e
00.020.050.040.030.040.0100.0100.210.671.512.8
--150.00-16.00-30.9520.69-68.57---20.005,025.00228.78123.7485.74
--------------
00000000000000
-0.03-0.05-0.06-0.11-0.19-0.25-0.44-0.65-0.74-0.79-0.56-0.150.321.51
-41.1827.0880.3370.0032.6275.8149.7713.946.72-29.72-73.48-318.24368.73
52.952.95954.8772.8180.63113.150000000
--------------
Details

Keystats

ⓘ

Revenue and Growth

The Revolution Medicines Revenue and Revenue Growth are pivotal to understanding the company's financial health and operational efficiency. A consistent increase in revenue indicates a company’s ability to effectively market and sell its products or services, while the revenue growth percentage offers insights into the pace at which the company is expanding over the years.

Gross Margin

The Gross Margin is a crucial metric that showcases the percentage of revenue exceeding the cost of goods sold (COGS). A higher gross margin is indicative of a company’s efficiency in controlling its production costs, thereby promising potential profitability and financial stability.

EBIT and EBIT Margin

EBIT (Earnings Before Interest and Taxes) and EBIT Margin offer deep insights into a company’s profitability, excluding the impacts of interest and taxes. Investors often assess these metrics to gauge the operational efficiency and inherent profitability of a business, separate from its financial structure and tax environment.

Income and Growth

Net Income and its subsequent growth are quintessential for investors looking to understand a company’s profitability. Consistent income growth underscores a company’s ability to enhance its profitability over time, reflecting operational efficiency, strategic competitiveness, and financial health.

Shares Outstanding

Shares outstanding refer to the total number of shares a company has issued. It's instrumental in calculating key metrics like Earnings Per Share (EPS) which is pivotal for investors to evaluate a company’s profitability on a per-share basis, offering a more granular view of financial health and valuation.

Interpreting Year to Year Comparison

Comparing yearly data allows investors to identify trends, assess the company’s growth, and anticipate potential future performance. Analyzing how metrics like revenue, income, and margins change year over year can provide valuable insights into the company’s operational efficiency, competitiveness, and overall financial health.

Expectations and Predictions

Investors often juxtapose the current and past financial data with the market’s expectations. This comparison aids in assessing whether the Revolution Medicines is performing as anticipated, underperforming or outperforming the market predictions, providing pivotal data for investment decisions.

 
ASSETSCASH BALANCE (B)RECEIVABLES (M)OTHER REC. (M)INVENTORIES (M)OTHER CURRENT LIAB. (M)CURRENT ASSETS (B)TANGIBLE ASSETS (M)LONG-T. INVEST. (M)LONG-T. REC. (M)INTANGIBLE ASSETS (M)GOODWILL (M)OTHER NON-CURRENT ASSETS (M)NON-CURRENT ASSETS (M)TOTAL ASSETS (B)LIABILITIESCOMMON STOCK (M)ADDITIONAL PAID-IN CAPITAL (B)RETAINED EARNINGS (M)OTHER EQUITY (M)UNREAL. GAINS/LOSSES (k)EQUITY (B)LIABILITIES (M)PROVISIONS (M)OTHER SHORT-TERM LIAB. (M)SHORT-TERM DEBTS (M)LONG-TERM DEBT PORTION (k)SHORT-TERM REC. (M)LONG-T. LIAB. (k)DEFERRED TAXES (M)OTHER LIAB. (M)LONG-T. LIABILITIES (M)DEBT (M)TOTAL CAPITAL (B)
2017201820192020202120222023
             
0.010.070.120.440.580.641.85
00005.94.71.25
0000000
0000000
0.48.52.576.810.625.07
0.010.080.130.450.590.661.88
5.36.97.136.371.273.7100.01
0000000
0000000
063.16260.959.958.857.74
014.614.614.614.614.614.61
0.40.62.81.42.54.610.06
5.785.286.5113.2148.2151.7182.42
0.020.160.210.560.740.812.06
             
72.2205.1305.10000.02
0000.741.061.392.96
-67.9-109.7-157.4-265.5-452.6-701.3-1,137.71
0000000
00100100-400-1,800544
00.10.150.470.60.691.83
3.45.211.412.614.121.361.79
3.27.112.922.433.635.778.17
1.11818.612.212.753.9
0000000
01002000000
7.730.443.147.260.462143.85
020000000
012.27.87.47.473.12
2.93117.138.167.657.788.55
2.943.424.945.57564.791.66
10.673.86892.7135.4126.7235.51
0.020.170.220.570.740.812.06
Details

Balance Sheet

ⓘ

Understanding the Balance Sheet

The balance sheet of Revolution Medicines provides a detailed financial snapshot, revealing the company's assets, liabilities, and equity at a specific point in time. Analyzing these components is crucial for investors looking to understand Revolution Medicines's financial health and stability.

Assets

Revolution Medicines's assets represent everything the company owns or controls that has monetary value. These are categorized into current and non-current assets, offering insights into the company's liquidity and long-term investments.

Liabilities

Liabilities are obligations that Revolution Medicines must settle in the future. Analyzing the ratio of liabilities to assets provides insights into the company's financial leverage and risk exposure.

Equity

Equity refers to the residual interest in the assets of Revolution Medicines after deducting liabilities. It represents the owners’ claim on the company’s assets and earnings.

Year-to-Year Analysis

Comparing balance sheet figures year-to-year allows investors to identify trends, growth patterns, and potential financial risks, facilitating informed investment decisions.

Interpreting the Data

Detailed analysis of assets, liabilities, and equity can provide investors with comprehensive insights into Revolution Medicines's financial standing, aiding in investment evaluations and risk assessments.

 
NET INCOME (M)DEPRECIATION (M)DEFERRED TAXES (M)CHANGES IN WORKING CAPITAL (M)NON-CASH ITEM (M)PAID INTEREST (M)PAID TAXES (M)NET CASH FLOW FROM OPERATING ACTIVITIES (k)CAPITAL EXPENDITURES (M)CASH FLOW FROM INVESTING ACTIVITIES (M)CASH FLOW FROM OTHER INVESTING ACTIVITIES (M)INTEREST INCOME AND EXPENSES (M)NET DEBT CHANGE (M)NET CHANGE IN EQUITY (M)CASH FLOW FROM FINANCING ACTIVITIES (B)CASH FLOW FROM OTHER FINANCING ACTIVITIES (M)TOTAL DIVIDENDS PAID (M)NET CHANGE IN CASH FLOW (M)FREE CASH FLOW (M)SHARE-BASED COMPENSATION (M)
2017201820192020202120222023
-31-41-47-108-187-248-436
1133456
00-4000-3
438-4-78-1340
046214763104
0000000
0000000
-25,0001,000-49,000-100,000-147,000-224,000-350,000
-1-1-2-2-6-10-7
-1-1-101-234-142-24-342
00-99-231-135-13-334
0000000
0000000
2260100422294301392
0.020.060.10.420.290.31.23
00-1000836
0000000
-460-5288452536
-26.73-0.29-52.21-102.99-153.71-235.22-358.3
0000000

Revolution Medicines stock margins

The Revolution Medicines margin analysis displays the gross margin, EBIT margin, as well as the profit margin of Revolution Medicines. The EBIT margin (EBIT/sales) indicates the percentage of sales that remains as operating profit. The profit margin shows the percentage of sales that remains for Revolution Medicines.

  • 3 years

  • 5 years

  • 10 years

  • 25 Years

  • Max

Gross margin
EBIT margin
Profit margin
Details

Margin

ⓘ

Understanding Gross Margin

The gross margin, expressed as a percentage, delineates the gross profit made from the Revolution Medicines's sales revenue. A higher gross margin percentage indicates that the Revolution Medicines retains more revenue after accounting for the costs of goods sold. Investors use this metric to gauge financial health and operational efficiency, as well as to compare it with competitors and industry averages.

EBIT Margin Analysis

EBIT margin represents the Revolution Medicines's earnings before interest and taxes. Analyzing the EBIT margin over different years provides insights into the operational profitability and efficiency, excluding the effects of financial leverage and tax structure. A growing EBIT margin over the years signifies improving operational performance.

Revenue Margin Insights

The revenue margin demonstrates the Revolution Medicines's total revenue generated. When comparing the revenue margin year over year, investors can gauge the Revolution Medicines's growth and market expansion. It is essential to compare the revenue margin with the gross and EBIT margins to understand the cost and profit structures better.

Interpreting Expectations

The expected values for gross, EBIT, and revenue margins provide future financial outlook of the Revolution Medicines. Investors should compare these expectations with historical data to understand potential growth and risk factors. It is crucial to consider the underlying assumptions and methodologies used in projecting these expected values to make informed investment decisions.

Comparative Analysis

Comparing the gross, EBIT, and revenue margins, both yearly and over multiple years, enables investors to perform a comprehensive analysis of the Revolution Medicines's financial health and growth prospects. Evaluating the trends and patterns in these margins helps in identifying strengths, weaknesses, and potential investment opportunities.

Revolution Medicines Margin History

Revolution Medicines Gross marginRevolution Medicines Profit marginRevolution Medicines EBIT marginRevolution Medicines Profit margin
2030e0 %0 %54.08 %
2029e0 %20.66 %21.48 %
2028e0 %-37.92 %-22.06 %
2027e0 %-313.91 %-271.79 %
2026e0 %-17,685.85 %-16,991.79 %
2025e0 %-12,846.49 %-12,447.88 %
2024e0 %-222,431.83 %-213,483.74 %
20230 %-4,207.12 %-3,768.28 %
20220 %-730.02 %-702.97 %
20210 %-639.71 %-636.58 %
20200 %-257.56 %-256.82 %
20190 %-108.15 %-123.7 %
20180 %-199.95 %-242.04 %
20170 %0 %0 %

Revolution Medicines Stock Sales Revenue, EBIT, Earnings per Share

The Revolution Medicines earnings per share therefore indicates how much revenue Revolution Medicines has generated per share in a given period. The earnings before interest and taxes per share shows how much of the operating profit corresponds to each share. The earnings per share indicates how much of the profit belongs to each share.

  • 3 years

  • 5 years

  • 10 years

  • 25 Years

  • Max

Sales per Share
EBIT per share
Earnings per Share
Details

Revenue, EBIT and Earnings per share

ⓘ

Revenue Per Share

Revenue per share represents the total revenue Revolution Medicines earns, divided by the number of outstanding shares. It is a crucial metric as it reflects the company's ability to generate sales and signifies growth and expansion potential. Comparing yearly revenue per share allows investors to analyze the consistency in a company’s earnings and predict future trends.

EBIT Per Share

EBIT per share indicates Revolution Medicines's earning before interest and taxes, offering insights into operational profitability excluding the effects of capital structure and tax rates. It can be juxtaposed against revenue per share to gauge the efficiency in converting sales into profits. A consistent increase in EBIT per share over the years underscores operational efficiency and profitability.

Income Per Share

Income per share, or earnings per share (EPS), reveals the portion of Revolution Medicines’s profit allocated to each share of common stock. It’s instrumental in evaluating the profitability and financial health. By comparing it with revenue and EBIT per share, investors discern how effectively a firm translates sales and operational profits into net income.

Expected Values

Expected values are projections of revenue, EBIT, and income per share for forthcoming years. These anticipations, rooted in historical data and market analysis, aid investors in strategizing their investments, evaluating Revolution Medicines's prospective performance, and estimating future stock prices. However, it’s pivotal to consider market volatilities and uncertainties that can influence these projections.

Revolution Medicines Revenue, EBIT and net profit per share

DateRevolution Medicines Sales per ShareRevolution Medicines EBIT per shareRevolution Medicines Earnings per Share
2030e15.2 undefined0 undefined8.22 undefined
2029e8.18 undefined0 undefined1.76 undefined
2028e3.66 undefined0 undefined-0.81 undefined
2027e1.12 undefined0 undefined-3.03 undefined
2026e0.03 undefined0 undefined-4.31 undefined
2025e0.03 undefined0 undefined-4.04 undefined
2024e0 undefined0 undefined-3.54 undefined
20230.1 undefined-4.31 undefined-3.86 undefined
20220.44 undefined-3.2 undefined-3.08 undefined
20210.4 undefined-2.58 undefined-2.57 undefined
20200.78 undefined-2.02 undefined-2.01 undefined
20190.85 undefined-0.92 undefined-1.05 undefined
20180.38 undefined-0.76 undefined-0.92 undefined
20170 undefined-0.59 undefined-0.66 undefined

Revolution Medicines business model

Revolution Medicines Inc is a biotechnology company specializing in the development of cancer medications. It was founded in 2014 in Redwood City, California. The company has received significant investment amounts in recent years and is focused on researching and developing personalized cancer therapies that act on a molecular level. They employ a new method called "in-situ imaging" for faster and more precise identification of treatment options. Revolution Medicines is divided into various areas including research and development of new drugs, collaboration with external partners, and conducting their own testing procedures. Their products include a variety of tailored cancer therapies, with RMC-4630 being one of their most promising therapies for advanced breast cancer. They have more products in development and aim to expand their development opportunities through partnerships with other companies in the cancer research field. This company aims to revolutionize cancer research by developing targeted therapies customized to meet individual patient needs, utilizing innovative methods and technologies. However, they face challenges in understanding and treating the complexity of molecular processes in cancer cells, as well as competition in the field. Overall, Revolution Medicines is a biotechnology company focused on shaping the future of cancer research. Revolution Medicines is one of the most popular companies on Eulerpool.com.

Revolution Medicines SWOT Analysis

Strengths

1. Revolutionary approach to medicine development and treatment.

2. Strong research and development capabilities.

3. Well-established partnerships with leading pharmaceutical companies.

4. Skilled and experienced team of scientists and professionals.

5. Excellent track record in achieving milestones and advancing pipeline.

Weaknesses

1. Relatively small market presence compared to established pharmaceutical companies.

2. Limited financial resources may restrict expansion and research endeavors.

3. High reliance on successful clinical trials for product approval and commercialization.

4. Vulnerability to regulatory changes and compliance requirements.

5. Potential difficulty in attracting and retaining top talent in a competitive industry.

Opportunities

1. Growing demand for targeted therapies and precision medicines.

2. Increasing investments in healthcare and life sciences.

3. Potential collaborations with academic institutions for research partnerships.

4. Expansion into new geographic markets to reach a wider patient population.

5. Emerging technologies like Artificial Intelligence for drug discovery.

Threats

1. Intense competition from large pharmaceutical companies.

2. Price pressures and reimbursement challenges in the healthcare industry.

3. Delays or failures in clinical trials leading to setbacks in product development.

4. Stringent regulatory requirements and potential delays in obtaining approvals.

5. Intellectual property infringement and legal disputes.

Revolution Medicines Revenue by Segment

  • 3 years

  • Max

Details

Revenue by Segment

ⓘ

Overview of Revenue by Segment

The chart visualizes revenues by segments and provides a clear overview of the revenue distribution. Each segment is clearly marked to facilitate comparisons of revenues.

Interpretation and Use

The chart enables quick identification of the highest-revenue segments, which is helpful in strategic decision-making. It supports the analysis of growth potentials and targeted resource allocation.

Investment Strategy

An investment strategy determines how capital is deliberately invested into various asset classes to maximize returns. It is based on risk tolerance, investment objectives, and a long-term plan.

Revolution Medicines Revenue by Segment

Segmente202220212020
Collaboration revenue related party--42.98 M USD
Collaboration revenue member35.38 M USD--
Collaboration Revenue-29.39 M USD-
LIMITED TIME OFFER

The World’s Best Investors Are On Eulerpool

Subscribe for $2

Revolution Medicines Eulerpool Fair Value

Details

Fair Value

ⓘ

Understanding Fair Value

The fair value of a stock provides insights into whether the stock is currently undervalued or overvalued. It is calculated based on profit, revenue, or dividends and offers a comprehensive perspective of the stock’s intrinsic value.

Income-Based Fair Value

This is calculated by multiplying the earnings per share by the average P/E ratio of the selected past years for smoothing. If the fair value is higher than the current market price, it suggests that the stock is undervalued.

Example 2022

Fair Value Profit 2022 = Earnings per Share 2022 / Average P/E Ratio 2019 - 2021 (3 Years Smoothing)

Revenue-Based Fair Value

It is derived by multiplying the revenue per share by the average price-to-sales ratio of the selected past years for smoothing. An undervalued stock is identified if the fair value exceeds the ongoing market price.

Example 2022

Fair Value Revenue 2022 = Revenue per Share 2022 / Average PSR 2019 - 2021 (3 Years Smoothing)

Dividend-Based Fair Value

This value is determined by dividing the dividend per share by the average dividend yield of the selected past years for smoothing. A higher fair value than the market price indicates an undervalued stock.

Example 2022

Fair Value Dividend 2022 = Dividend per Share 2022 * Average Dividend Yield 2019 - 2021 (3 Years Smoothing)

Expectations and Forecasts

Future expectations provide potential trajectories for stock prices and aid investors in decision-making. The expected values are forecasted figures of fair value, taking into account the growth or decline trends of profit, revenue, or dividend.

Comparative Analysis

Comparing the fair value based on profit, revenue, and dividend provides a holistic overview of the stock’s financial health. Observing the annual and per-annual variations contributes to understanding the consistency and reliability of stock performance.

Revolution Medicines historical P/E ratio, EBIT multiple, and P/S ratio

LIMITED TIME OFFER

The World’s Best Investors Are On Eulerpool

Subscribe for $2

Revolution Medicines shares outstanding

The number of shares was Revolution Medicines in 2024 — This indicates how many shares 113.15 M is divided into. Since shareholders are the owners of a company, each share represents a small portion of the company's ownership.

  • 3 years

  • 5 years

  • 10 years

  • 25 Years

  • Max

Number of stocks
Details

Revenue, EBIT and Earnings per share

ⓘ

Revenue Per Share

Revenue per share represents the total revenue Revolution Medicines earns, divided by the number of outstanding shares. It is a crucial metric as it reflects the company's ability to generate sales and signifies growth and expansion potential. Comparing yearly revenue per share allows investors to analyze the consistency in a company’s earnings and predict future trends.

EBIT Per Share

EBIT per share indicates Revolution Medicines's earning before interest and taxes, offering insights into operational profitability excluding the effects of capital structure and tax rates. It can be juxtaposed against revenue per share to gauge the efficiency in converting sales into profits. A consistent increase in EBIT per share over the years underscores operational efficiency and profitability.

Income Per Share

Income per share, or earnings per share (EPS), reveals the portion of Revolution Medicines’s profit allocated to each share of common stock. It’s instrumental in evaluating the profitability and financial health. By comparing it with revenue and EBIT per share, investors discern how effectively a firm translates sales and operational profits into net income.

Expected Values

Expected values are projections of revenue, EBIT, and income per share for forthcoming years. These anticipations, rooted in historical data and market analysis, aid investors in strategizing their investments, evaluating Revolution Medicines's prospective performance, and estimating future stock prices. However, it’s pivotal to consider market volatilities and uncertainties that can influence these projections.

LIMITED TIME OFFER

The World’s Best Investors Are On Eulerpool

Subscribe for $2
Unfortunately, there are currently no price targets and forecasts available for Revolution Medicines.

Revolution Medicines latest earnings and earnings surprises

DateEPS EstimateEPS ActualQuarterly report
9/30/2024-0.91 -0.94  (-3.17 %)2024 Q3
6/30/2024-0.79 -0.81  (-2.48 %)2024 Q2
3/31/2024-0.76 -0.7  (8.02 %)2024 Q1
12/31/2023-0.9 -1.14  (-26.71 %)2023 Q4
9/30/2023-1.03 -0.99  (3.23 %)2023 Q3
6/30/2023-0.84 -0.92  (-9.5 %)2023 Q2
3/31/2023-0.83 -0.72  (13.23 %)2023 Q1
12/31/2022-0.84 -0.63  (24.84 %)2022 Q4
9/30/2022-0.86 -0.87  (-1.27 %)2022 Q3
6/30/2022-0.87 -0.82  (5.39 %)2022 Q2
1
2

Eulerpool ESG Scorecard© for the Revolution Medicines stock

Eulerpool World ESG Rating (EESG©)

49/ 100

🌱 Environment

54

👫 Social

42

🏛️ Governance

50

Environment

Scope 1 - Direct Emissions
Scope 2 - Indirect emissions from purchased energy
Scope 3 - Indirect emissions within the value chain
Total CO₂ emissions
CO₂ reduction strategy
Coal energy
Nuclear power
Animal experiments
Fur & Leather
Pesticides
Palm Oil
Tobacco
Genetically modified organisms
Climate concept
Sustainable forestry
Recycling regulations
Environmentally friendly packaging
Hazardous substances
Fuel consumption and efficiency
Water consumption and efficiency

Social

Percentage of female employees56
Percentage of women in management
Percentage of Asian employees
Share of Asian management
Percentage of Hispanic/Latino employees
Hispano/Latino Management share
Percentage of Black employees
Black Management Share
Percentage of white employees
White Management Share
Adult content
Alcohol
Weapons
Firearms
Gambling
Military contracts
Human rights concept
Privacy concept
Occupational health and safety
Catholic

Governance (Corporate Governance)

Environmental reporting
Stakeholder Engagement
Call Back Policies
Antitrust law

The Eulerpool ESG Scorecard© is the strictly copyrighted intellectual property of Eulerpool Research Systems. Any unauthorized use, imitation, or infringement will be actively pursued and may lead to significant legal consequences. For licenses, collaborations, or usage rights, please contact us directly via our contact form. Contact Form to us.

Revolution Medicines shareholders

%
Name
Stocks
Change
Date
9.26080 % The Vanguard Group, Inc.17,069,5002,183,61712/31/2024
7.18788 % Farallon Capital Management, L.L.C.13,248,6921,931,00012/31/2024
6.85477 % BlackRock Institutional Trust Company, N.A.12,634,7071,077,41112/31/2024
5.87114 % Wellington Management Company, LLP10,821,691-579,70312/31/2024
5.14540 % Janus Henderson Investors9,483,9993,346,75512/31/2024
4.30608 % Baker Bros. Advisors LP7,936,972367,88212/31/2024
4.12385 % Nextech Invest, Ltd.7,601,0871,304,34712/31/2024
3.55529 % Paradigm BioCapital Advisors LP6,553,1111,239,02212/31/2024
3.54198 % Fidelity Management & Research Company LLC6,528,585653,67612/31/2024
3.14223 % State Street Global Advisors (US)5,791,752512,16812/31/2024
1
2
3
4
5
...
10

Revolution Medicines Executives and Management Board

Dr. Mark Goldsmith

(61)
Revolution Medicines Chairman of the Board, President, Chief Executive Officer (since 2014)
Compensation 7.22 M

Dr. Steve Kelsey

(62)
Revolution Medicines President - Research and Development
Compensation 3.08 M

Ms. Margaret Horn

(60)
Revolution Medicines Chief Operating Officer
Compensation 3.08 M

Mr. Jack Anders

(46)
Revolution Medicines Chief Financial Officer (since 2022)
Compensation 1.95 M

Ms. Xiaolin Wang

(53)
Revolution Medicines Executive Vice President - Clinical Development
Compensation 1.79 M
1
2
3
4

Revolution Medicines Supply Chain

NameRelationshipTwo-week correlationOne-month correlationThree-Month CorrelationSix-Month CorrelationOne Year CorrelationTwo-Year Correlation
Sanofi Stock
Sanofi
SupplierCustomer0,410,49-0,07-0,46-0,66-0,76
Amgen Stock
Amgen
SupplierCustomer0,35-0,750,25-0,25-0,260,11
1

Most common questions regarding Revolution Medicines

What values and corporate philosophy does Revolution Medicines represent?

Revolution Medicines Inc is driven by a strong set of values and corporate philosophy. The company is dedicated to transforming patient lives by targeting frontier targets within notorious cancer-promoting pathways. Revolution Medicines utilizes a precision oncology approach to create innovative therapies that selectively inhibit drivers of cancerous growth. Their research and development efforts focus on identifying vulnerabilities in cancer cells, leading to the discovery of potential breakthrough treatments. By collaborating with academic institutions and industry leaders, Revolution Medicines is committed to advancing scientific knowledge and delivering novel therapies to patients in need. With their patient-centric approach and commitment to scientific excellence, Revolution Medicines Inc aims to revolutionize the field of oncology.

In which countries and regions is Revolution Medicines primarily present?

Revolution Medicines Inc is primarily present in the United States.

What significant milestones has the company Revolution Medicines achieved?

Revolution Medicines Inc has achieved several significant milestones. The company successfully completed its initial public offering (IPO) in 2020, raising substantial funds for its innovative drug discovery and development programs. Revolution Medicines Inc also received the Breakthrough Therapy Designation from the U.S. FDA for its targeted therapy, RMC-4630, in 2021. This designation highlights the potential of RMC-4630 to address unmet medical needs in patients with specific cancer mutations. Additionally, the company has forged several strategic collaborations with renowned institutions and pharmaceutical companies, further validating its pioneering approach towards precision medicine. Revolution Medicines Inc's milestone achievements reflect its commitment to advancing patient care through novel therapies and collaborations within the pharmaceutical industry.

What is the history and background of the company Revolution Medicines?

Revolution Medicines Inc. is a leading biopharmaceutical company focused on developing innovative precision therapies targeting frontier oncology targets. Founded in 2014, Revolution Medicines aims to address the unmet needs of patients with genomically defined cancers. The company utilizes a proprietary drug discovery platform, called the Restricted Pharmacophoric Space (RPS), to systematically explore the vastness of chemical space. This approach enables the identification of novel small molecule modulators for challenging, yet high-value, cancer targets. Revolution Medicines leverages its expertise and strategic partnerships to advance its pipeline, with the ultimate goal of transforming the lives of patients through the discovery and development of transformative medicines.

Who are the main competitors of Revolution Medicines in the market?

The main competitors of Revolution Medicines Inc in the market include companies such as Mirati Therapeutics Inc, Turning Point Therapeutics Inc, Nektar Therapeutics, Blueprint Medicines Corporation, and Ideaya Biosciences Inc.

In which industries is Revolution Medicines primarily active?

Revolution Medicines Inc is primarily active in the biotechnology and pharmaceutical industries. As a leading company in the field, Revolution Medicines focuses on discovering and developing innovative therapies for patients with serious diseases, including those with cancer. By using their proprietary drug discovery platform, the company aims to identify and target important pathways and drivers of diseases, transforming the lives of patients worldwide. Revolution Medicines Inc strives to make groundbreaking advancements in the biotech and pharmaceutical sectors to improve healthcare and contribute to the overall well-being of individuals.

What is the business model of Revolution Medicines?

Revolution Medicines Inc is a biotechnology company focused on discovering and developing new treatments for patients with cancer. Their business model is centered around the discovery and advancement of innovative, precision oncology therapies. By leveraging their expertise in targeted therapies, Revolution Medicines aims to develop breakthrough medicines that specifically target the underlying drivers of cancer. Through strategic collaborations and internal research and development efforts, the company aims to bring transformative treatments to patients in need. Revolution Medicines Inc is committed to advancing the field of precision oncology and making a meaningful impact on patients' lives.

What is the P/E ratio of Revolution Medicines 2025?

The Revolution Medicines P/E ratio is -6.28.

What is the P/S ratio of Revolution Medicines 2025?

The Revolution Medicines P/S ratio is 781.69.

What is the Quality Investing of Revolution Medicines?

The Quality Investing for Revolution Medicines is 2/10.

What is the revenue of Revolution Medicines 2025?

The expected Revolution Medicines revenue is 5.98 M USD.

How high is the profit of Revolution Medicines 2025?

The expected Revolution Medicines profit is -744.88 M USD.

What is the business model of Revolution Medicines

Revolution Medicines Inc is a biotechnology company focused on researching and developing cancer drugs. Their business model is based on identifying cancer cell-specific target molecules and developing drugs that specifically target these molecules. The company has developed a proprietary drug discovery platform that allows them to understand the structural complexity of cancer cells as well as their metabolic pathways, and identify specific targets for new drugs. The platform uses a combination of bioinformatics methods, chemistry, and genomics and has been used to develop drugs for serious types of cancer such as breast, colorectal, and lung cancer. Revolution Medicines' product portfolio includes a variety of drug candidates at different stages of preclinical and clinical development. Some of the most promising candidates are RMC-4630, RMC-5552, and RMC-5845, which are currently in Phase 1 and 2 clinical trials. RMC-4630 is an inhibitor for the KRAS oncogene, which is mutated in numerous cancer types but has been difficult to treat. RMC-5552 is a specific inhibitor of the SHP2 protein, which stimulates growth in many types of cancer. RMC-5845 blocks the activity of an enzyme called SHMT2, which may play a crucial role in cancer development. Revolution Medicines has also entered into a collaboration agreement with Sanofi to jointly develop new drugs based on its proprietary platform. Under the agreement, the company will receive up to $560 million in total, and both companies will share the profits generated. The company also has a promising pipeline of additional drug candidates currently in preclinical development, including inhibitors for other cancer-specific target molecules. Additionally, the company has developed a spin-off platform called Revolution AgRx, which uses similar approaches to develop new agricultural chemicals. In summary, Revolution Medicines' business model focuses on developing innovative drugs for the treatment of cancer. The company utilizes its proprietary drug discovery platform to identify specific target molecules and develop new drugs that target these molecules. Revolution Medicines has a wide range of drug candidates at different stages of development and has a collaboration agreement with Sanofi to jointly develop new drugs.

What is the Revolution Medicines dividend?

Revolution Medicines pays a dividend of 0 USD distributed over payouts per year.

How often does Revolution Medicines pay dividends?

The dividend cannot currently be calculated for Revolution Medicines or the company does not pay out a dividend.

What is the Revolution Medicines ISIN?

The ISIN of Revolution Medicines is US76155X1000.

What is the Revolution Medicines WKN?

The WKN of Revolution Medicines is A2PYWG.

What is the Revolution Medicines ticker?

The ticker of Revolution Medicines is RVMD.

How much dividend does Revolution Medicines pay?

Over the past 12 months, Revolution Medicines paid a dividend of . This corresponds to a dividend yield of about . For the coming 12 months, Revolution Medicines is expected to pay a dividend of 0 USD.

What is the dividend yield of Revolution Medicines?

The current dividend yield of Revolution Medicines is .

When does Revolution Medicines pay dividends?

Revolution Medicines pays a quarterly dividend. This is distributed in the months of .

How secure is the dividend of Revolution Medicines?

Revolution Medicines paid dividends every year for the past 0 years.

What is the dividend of Revolution Medicines?

For the upcoming 12 months, dividends amounting to 0 USD are expected. This corresponds to a dividend yield of 0 %.

In which sector is Revolution Medicines located?

Revolution Medicines is assigned to the 'Health' sector.

Wann musste ich die Aktien von Revolution Medicines kaufen, um die vorherige Dividende zu erhalten?

To receive the latest dividend of Revolution Medicines from 2/26/2025 amounting to 0 USD, you needed to have the stock in your portfolio before the ex-date on 2/26/2025.

When did Revolution Medicines pay the last dividend?

The last dividend was paid out on 2/26/2025.

What was the dividend of Revolution Medicines in the year 2024?

In the year 2024, Revolution Medicines distributed 0 USD as dividends.

In which currency does Revolution Medicines pay out the dividend?

The dividends of Revolution Medicines are distributed in USD.

All fundamentals about Revolution Medicines

Our stock analysis for Revolution Medicines Revenue stock includes important financial indicators such as revenue, profit, P/E ratio, P/S ratio, EBIT, as well as information on dividends. We also assess aspects such as stocks, market capitalization, debt, equity, and liabilities of Revolution Medicines Revenue. If you are looking for more detailed information on these topics, we offer comprehensive analyses on our subpages.